       Document 0929
 DOCN  M9620929
 TI    Progress in AIDS vaccine development.
 DT    9602
 AU    Johnston MI; Division of AIDS, National Institute of Allergy and
       Infectious; Diseases, National Institutes of Health, Bethesda, MD
       20892-7620,; USA.
 SO    Int Arch Allergy Immunol. 1995 Dec;108(4):313-7. Unique Identifier :
       AIDSLINE MED/96071808
 AB    Because of a unique combination of challenges facing human
       immunodeficiency virus vaccine developers, a number of traditional and
       novel vaccine designs are being evaluated essentially in parallel.
       Monomeric proteins, poxvirus vectors, peptides, and particle-based
       candidate vaccines have entered or will soon enter human trials. Other
       designs are at earlier stages of development. All candidates evaluated
       to date in phase I/II human trials have proven safe and immunogenic. One
       or more of the most promising designs will soon progress to 'test of
       concept' clinical trials to determine efficacy.
 DE    Acquired Immunodeficiency Syndrome/*PREVENTION & CONTROL/  TRANSMISSION
       Animal  AIDS Vaccines/*IMMUNOLOGY  Clinical Trials, Phase I  Clinical
       Trials, Phase II  Drug Design  Gene Products, env/IMMUNOLOGY  Gene
       Products, gag/IMMUNOLOGY  Human  HIV Antigens/IMMUNOLOGY  HIV
       Infections/PREVENTION & CONTROL/TRANSMISSION  Poxviridae/GENETICS
       Vaccines, Synthetic/IMMUNOLOGY  JOURNAL ARTICLE  REVIEW  REVIEW,
       TUTORIAL

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).

